Brendan M Everett

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5425845/publications.pdf

Version: 2024-02-01

72	15,986	94381 37	88593 70
papers	citations	h-index	g-index

73	73	73	20236
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine, 2017, 377, 1119-1131.	13.9	6,227
2	Effect of interleukin-1Î² inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet, The, 2017, 390, 1833-1842.	6.3	948
3	Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. New England Journal of Medicine, 2019, 380, 752-762.	13.9	886
4	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 790-802.	13.9	778
5	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 777-789.	13.9	712
6	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet, The, 2018, 391, 319-328.	6.3	628
7	Effects of Interleukin-1Î² Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen. Circulation, 2012, 126, 2739-2748.	1.6	481
8	Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. Circulation, 2019, 139, 1289-1299.	1.6	384
9	Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). European Heart Journal, 2018, 39, 3499-3507.	1.0	375
10	Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis. American Heart Journal, 2013, 166, 199-207.e15.	1.2	347
11	Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. American Heart Journal, 2018, 206, 80-93.	1.2	276
12	2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes. Journal of the American College of Cardiology, 2020, 76, 1117-1145.	1.2	276
13	2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology, 2018, 72, 3200-3223.	1.2	251
14	Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the American College of Cardiology, 2018, 71, 2392-2401.	1.2	236
15	Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. European Heart Journal, 2016, 37, 2428-2437.	1.0	200
16	Inhibition of Interleukin-1Î² by Canakinumab and Cardiovascular Outcomes in Patients With ChronicÂKidney Disease. Journal of the American College of Cardiology, 2018, 71, 2405-2414.	1.2	186
17	Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 1703.	3.8	186
18	Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. Lancet Diabetes and Endocrinology,the, 2016, 4, 840-849.	5.5	159

#	Article	IF	Citations
19	Rosuvastatin in the Prevention of Stroke Among Men and Women With Elevated Levels of C-Reactive Protein. Circulation, 2010, 121, 143-150.	1.6	157
20	Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. Diabetes Care, 2019, 42, 2298-2306.	4.3	157
21	Interaction of Impaired Coronary Flow Reserve and Cardiomyocyte Injury on Adverse Cardiovascular Outcomes in Patients Without Overt Coronary Artery Disease. Circulation, 2015, 131, 528-535.	1.6	135
22	Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ: British Medical Journal, 2018, 360, k119.	2.4	132
23	Novel Genetic Markers Associate With Atrial Fibrillation Risk in Europeans and Japanese. Journal of the American College of Cardiology, 2014, 63, 1200-1210.	1.2	127
24	Adverse Effects of Low-Dose Methotrexate. Annals of Internal Medicine, 2020, 172, 369.	2.0	126
25	Reducing LDL with PCSK9 Inhibitors â€" The Clinical Benefit of Lipid Drugs. New England Journal of Medicine, 2015, 373, 1588-1591.	13.9	120
26	High-Sensitivity Cardiac Troponin I and B-Type Natriuretic Peptide as Predictors of Vascular Events in Primary Prevention. Circulation, 2015, 131, 1851-1860.	1.6	113
27	Inhibition of Interleukin-1Î² and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial. Journal of the American College of Cardiology, 2020, 76, 1660-1670.	1.2	110
28	The Relative Strength of C-Reactive Protein and Lipid Levels as Determinants of Ischemic Stroke Compared With Coronary Heart Disease in Women. Journal of the American College of Cardiology, 2006, 48, 2235-2242.	1.2	109
29	Sensitive Cardiac Troponin T Assay and the Risk of Incident Cardiovascular Disease in Women With and Without Diabetes Mellitus. Circulation, 2011, 123, 2811-2818.	1.6	106
30	Physical Activity and the Risk of Incident Atrial Fibrillation in Women. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 321-327.	0.9	105
31	Novel Antiatherosclerotic Therapies. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 538-545.	1.1	103
32	Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Nonâ€"Critically Ill Hospitalized Patients With COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 227.	3.8	89
33	Prevalence of Heparin/Platelet Factor 4 Antibodies Before and After Cardiac Surgery. Annals of Thoracic Surgery, 2007, 83, 592-597.	0.7	76
34	Relationship of Interleukin-1Î² Blockade With Incident Gout and Serum Uric Acid Levels. Annals of Internal Medicine, 2018, 169, 535.	2.0	74
35	Race/Ethnicity and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2017, 69, 1823-1831.	2.9	70
36	Sodiumâ€"Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Annals of Internal Medicine, 2021, 174, 1528-1541.	2.0	52

#	Article	IF	Citations
37	Interleukin-18 and the risk of future cardiovascular disease among initially healthy women. Atherosclerosis, 2009, 202, 282-288.	0.4	39
38	Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: A prespecified subgroup analysis of a community-based, randomized, open-label trial. Clinical Therapeutics, 2008, 30, 661-672.	1.1	32
39	Dyslipidemia Profiles in Patients with Peripheral Artery Disease. Current Cardiology Reports, 2019, 21, 42.	1.3	30
40	Targeting Inflammation to Reduce Residual Cardiovascular Risk. Current Atherosclerosis Reports, 2020, 22, 66.	2.0	29
41	Hypoglycemia and Elevated Troponin in Patients With Diabetes and CoronaryÂArtery Disease. Journal of the American College of Cardiology, 2018, 72, 1778-1786.	1.2	26
42	B-Type Natriuretic Peptides Improve Cardiovascular Disease Risk Prediction in a Cohort of Women. Journal of the American College of Cardiology, 2014, 64, 1789-1797.	1.2	25
43	Comparative Risks of Cardiovascular Disease in Patients With Systemic Lupus Erythematosus, Diabetes Mellitus, and in General Medicaid Recipients. Arthritis Care and Research, 2020, 72, 1431-1439.	1.5	24
44	Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. European Journal of Heart Failure, 2022, 24, 169-180.	2.9	23
45	Heart failure risk in systemic lupus erythematosus compared to diabetes mellitus and general medicaid patients. Seminars in Arthritis and Rheumatism, 2019, 49, 389-395.	1.6	22
46	Comparison of an administrative algorithm for SLE disease severity to clinical SLE Disease Activity Index scores. Rheumatology International, 2020, 40, 257-261.	1.5	20
47	Markers of Myocardial Stress, Myocardial Injury, and Subclinical Inflammation and the Risk of Sudden Death. Circulation, 2020, 142, 1148-1158.	1.6	19
48	Racial/ethnic variation in stroke rates and risks among patients with systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 2019, 48, 840-846.	1.6	18
49	Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies Among US Medicare Beneficiaries Between 2012 and 2017. JAMA Internal Medicine, 2020, 180, 141.	2.6	17
50	Initial disease severity, cardiovascular events and all-cause mortality among patients with systemic lupus erythematosus. Rheumatology, 2020, 59, 495-504.	0.9	16
51	Lipid Testing and Statin Prescriptions Among Medicaid Recipients With Systemic Lupus Erythematosus or Diabetes Mellitus and the General Medicaid Population. Arthritis Care and Research, 2019, 71, 104-115.	1.5	15
52	Association Between Markers of Inflammation and Total Stroke by Hypertensive Status Among Women. American Journal of Hypertension, 2016, 29, 1117-1124.	1.0	13
53	Impact of Changes in Inflammation on Estimated Tenâ€Year Cardiovascular Risk in Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 1392-1398.	2.9	13
54	Medicaid Expansion and Utilization of Antihyperglycemic Therapies. Diabetes Care, 2020, 43, 2684-2690.	4.3	13

#	Article	IF	Citations
55	Atrial Fibrillation/flutter Hospitalizations among US Medicaid Recipients with and without Systemic Lupus Erythematosus. Journal of Rheumatology, 2020, 47, 1359-1365.	1.0	12
56	Statins in Peripheral Artery Disease. Circulation, 2018, 137, 1447-1449.	1.6	11
57	Residual Inflammatory Risk. Journal of the American College of Cardiology, 2019, 73, 2410-2412.	1.2	11
58	Impact of Modifiable Risk Factors on B-type Natriuretic Peptide and Cardiac Troponin T Concentrations. American Journal of Cardiology, 2016, 117, 376-381.	0.7	10
59	Cardiac troponin as a novel tool for cardiovascular risk prediction in ambulatory populations. Trends in Cardiovascular Medicine, 2017, 27, 41-47.	2.3	8
60	Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ, The, 2020, 370, m2812.	3.0	7
61	Heart Failure, the Inflammasome, andÂInterleukin-1Î². Journal of the American College of Cardiology, 2019, 73, 1026-1028.	1.2	6
62	Cardiac Involvement in Athletes Recovering From COVID-19: A Reason for Hope. Circulation, 2021, 144, 267-270.	1.6	6
63	Comparative risks of cardiovascular disease events among SLE patients receiving immunosuppressive medications. Rheumatology, 2021, 60, 3789-3798.	0.9	5
64	Response to Letter Regarding Article, â€œLipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (Justification for the Use of Statins in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 37	1.6	4
65	Using inflammatory biomarkers to guide lipid therapy. Current Cardiovascular Risk Reports, 2008, 2, 29-34.	0.8	3
66	Finding Efficacy in a Safety Trial. Circulation, 2016, 134, 773-775.	1.6	3
67	Causal mediation analysis of the relationship of canakinumab's effect against subsequent gout flares and highâ€sensitivity Câ€reactive protein in <scp>CANTOS</scp>. Arthritis Care and Research, 2021, , .	1.5	3
68	Assessing the Effects of Diet and Behavior on Cardiovascular Disease: The Role of Biomarkers in Understanding Biology and Mechanism. Clinical Chemistry, 2016, 62, 1169-1171.	1.5	1
69	Reply. Journal of the American College of Cardiology, 2018, 72, 1432-1433.	1.2	1
70	CS-19â€…Heart failure hospitalizations among SLE and diabetes mellitus patients compared to the general U.S. medicaid population. , 2018, , .		0
71	Sodiumâ€“Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Annals of Internal Medicine, 2022, 175, W4.	2.0	0
72	Sodiumâ€“Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Annals of Internal Medicine, 2022, 175, W4-W5.	2.0	0